(12)
M
(54)
P4
Al
S(
(76) In
(*) N,
(21) AI
(22) Fi
(65)
U~
(60) Pr
13
(51 ) In
Af,
C.J
~ATENT
TERM NOTICE
If the application for this p atent was f iled on or after June 8, 1995, th e tenn of this
patent begins on the date on which this patent issues and ends twen~v years from th e
filing date of the application Of; if the application contains a specific reference to' an
earlier filed application or applications under 35 U Sc. 120, 121, or 365(c) , twenry
years Fom the filing date of the earliest such application ( "the t\venty-year term "),
subject to the payment of maintenance fees as provided by 35 USc. 41(b), and any
extension as provided by 35 U Sc. J54 (b) or 156 or any disclaimer under 35 US C.
253.
If this application was filed prior to June 8, J995, the term of this p atent begins on the
date on which this patent issues and ends on the later ofseventeen years f rom the date
of the grant of this patent or the twenty-year term set forth above jiJr patents resulting
fro m applications filed on or after June 8, 1995, subject to the payment of maintenance
f ees as provided by 35 U S c. 41 (b) and any extension as provided by 35 u.S.C 156 or
any disclaimer under 35 US C 253,
ct
C~
(52)
U.
(5!l) Fil
Sc
(56)
(>,31
6,42
6,66
6,87
2006/02:
2007102,
Yan el al. I
Bordicr C.
Pen'Y B.
Certilkad,
Caslenacia
lransmisiu
111111
11111111111111111111111111111111111111111111111111111 1
11111111
US008097284B2
(12)
(10)
Mikaelian
(45)
Inventor:
( *)
Notice:
(21)
(22)
Filed:
Nov. 13,2008
(65)
May 14,2009
(51 )
Int. CI.
A61K 35/24
(2006.0 I)
CI2N 9/00
(2006.01)
(2006.01)
C07K 1100
21104
(2006.01 )
(52) U.S. CI. ....... 424/537; 435/183; 5301350; 536123.1;
com
536/23.2
(58) Field of Classification Search ........................ None
See application file for complete search history.
(56)
References Cited
U.S. PATENT DOCUMENTS
6,319.891
6.429,187
6,667,156
6,870.029
2006/0252676.
2007/0237714
BI
BI
B2
B2
AI
AI
11/2001
8/2002
12/2003
3/2005
11/2006
10/2007
Sontheimer
Sontheimer
Sontheimer et al.
Sontheimer
Zhang et al.
Alvarez
OTHER PUBLICATIONS
Yan et al. Peptides. OCl. 12, 2010'
Patent No.:
Date of Patent:
US 8,097,284 B2
Jan. 17,2012
toxin. in rat by plantar injection. Brain Res. 2002; 952 2, pp. 322-326.
136: 1-12.
Dint L, Coppola S, Ruzittu MI. Ghibelli L. Multiple pathways for
apoptotic nuclear fragmentation. Exp Cell Res Mar. 15, 1996;
223(2):340-7.
Guan, R.J .. Wang. C.G., Wand, M. and Wang. D.C. A depressant
insect toxin with a novel' analgesic effect from scorpion BII/hus
Inllrtensii Karsch. Biochim. Biophys. Acta 200 I; 1549 I, pp. 9-18.
Guan. R.J., Wang, M., Wang. D. and Wang, D.C. A new insect
neurotoxin AngP I with analgesic effect from the scorpion Bu/hus
mal'/ellsi Karsch: purification and characterization. J. Pepl. Res.
2001 ;58 10. pp. 27-35.
Kourie, J.I .. Shorthouse, A.A., Properties of cytotoxic peptide
fonTied ion channels. Am J Physiol Cell Physiol 2000; 278: 1063
1087.
Liu. YE. MA, RL. Wang. S.t., Duan, Z. Y, Zhang, J.H., Wu L.J. and
Wu, C.F Expression of an antitumor-analgesic peptide from the
venom of Chinese scorpion Bu/hus mllriellSi Karsch in Escherichill
coli. Protein bpr Purif. 2003; 27 2, pp. 253-258.
Omran, M A. Cytotoxic and apoptotic effects of scorpion Leil/rus
4l1ill4l/es/l'illlllS venom on 293T and C2C 12 eukaryotic cell lines. J
Venom Anim Toxins incl Trop Dis 2003; 9(2):255-76.
Rajendra. w., Arunmozhiarasi, A., Jeyaseelan, K. Toxins in anti
nociception and anti-inflammation. Toxicon; 2004 44 l, pp. 1-17.
Xiong. YM., Lan, Z.D., Wang, M., Liu, B., Liu, X.Q. Molecular
characterization of a new insect neurotoxin with an analgesic effect
on mice from the scorpion Bu/hus marlensi Karsch. Toxicon 1999;37
8, pp. 1165-1180.
* cited by examiner
Primary Examiner - Christian Fronda
(74) AI/orney, Agent, or Firm - Marc E. Hankin; Kevin
Schraven; Hank i,n Patent Law, APC
(57)
ABSTRACT
u.s. Patent
40
6)
...
dI
tIS
c:
~" .
19%
..,..
4 1A>
20
US 8,097,284 B2
Sheet 1 of9
0%
30
t
Se
Jan. 17,2012
~1
33%
36%
40%
55%
,Ll
l
!
10
43%
0
Cont - Parace
tamol
5
Venom
10
15
CoflC~f'lt.r.
Experiental Groups
Fi bour 1
20
tion (m g/Kg)
50
_I
u.s. Patent
14
.-
G).
Jan. 17,2012
0%
37%
36%
t ""-'
-.
54%
G>
US 8,097,284 B2
Sheet 2 of 9
", .
o ~----~----~~~--~~--~--~--~
Co
..
__ __................ .....
o )C
1M
5fllJIkg
orrgfkg
Experimental Groups
Figure 2
u.s. Patent
'120
Jan. 17,2012
US 8,097,284 B2
Sheet 3 of9
-+- fibroblast
l
,
-...-uterus
- :i;- Iun '~l
'0'
-+-
-/l)
0.75
venom concentrati on (mg/kg)
Figure 3
larvn x
J
u.s. Patent
Jan. 17,2012
US 8,097,284 B2
Sheet 4 of9
'140
".-.,
E
E
-~
Il)
,(J1
Venom
'120
Dose (mglt( g)
'100
0,00
0,06
80
50
1.0
!....
E
:J
40
?n
~
o
'
O '14 2'1:
'JI:.
L:.J
10
L t,.)
0
",)
__IL
q-r,
.....
.1
ti me of tu rnor gro\jl,1rJ(days)
Figure 4
'J ,
.J
u.s. Patent
Jan. 17,2012
Sheet 5 of 9
US 8,097,284 B2
40o/L
20
/*-
0/0--
Day
J 41 61 8110112114'16118'201241
Figure 5
U.S. Patent
Jao.17,2012
US 8,097,284 B2
Sheet 6 of9
!1
c;
~-
<I>
.....
c..
.....
0
Q)
-...
Cl
'42.00%
i
- :17.50% --'
C
CD
<I>
c..
-~
(tI
E
0
-~
.....(tI
-+-'
0
......
(I)
(f)
a..
>-.
0 "
>.
.-
OJ
0.00%
~34m~ ~
"'0
(tI
ro
;;;J
ro
.0
OJ
r.....o E
0
OJ ....-0 a..
0 E
~>.
C/)
E
0
.......
E --
OJ . ~
'
......
E
A
(f)
-0
::>
E
....
Q.)
--
:r:
:z
Larynx Cancer
Figure 6
;>-. ....
::>,
>.
a..
:.:.:::.
co
0
(,,)
>'''
';-"'O,~O" O"-%
OJ~
UJ.8
a..
E
>.
(f)
..c
0
U.S. Patent
Jan. 17,2012
US 8,097,284 B2
Sheet 7 of 9
- -- - -
<I>
0:1
c:
:;;
a..
----
-----
----~
--- -
0
<I>
0'1
...'"c:
<I>
(,)
0
(I)
a..
' .
.~
co
-...~
co
E
0
......
....0
0..
>.
en
0..
>.
:::::
(f)
CO
TI
'-
~ #.;::
.....
(l)
co
co E
0
'-
Q)--
-00..
~
(f)
-~
-0
c::
.s::::.
......
::J
.0
(1)
.....
co
0
......
0..
(f)
>.
>
(1) . ~
...x E
'-
wE0
Q)
(/)
Lung Cancer
Fi gure 7
E~
:r
CO
'
'- (1) ..,,
0
>.
<U
u.s. Patent
Jan. 17,2012
US 8,097,284 B2
Sheet 8 of9
!!
c
.,,
.~
r.l
Q..
..
01
1'#
".
~~
Q..
(.)
ro
.:2
......
co
0
.....0..
0
.....0..
""'
c
>
(/)
<.
-co
E
'
0
>
en
_ .....
(.)
>-'
<1> ctI
ctI E
L 0
.....
(I) ......
0..
-gE
2~
-0
,9
(.)
0 ..
:>.
(f)
>
>
~
::E
(1)2
E
(1).2
.!:; E
Xo
UJ .....
0..
(])
Uterine Cancer
Fiourc
8
b
>-'
c:
:::J
:>
.....m
:>'.
(f)
.c:
+-'
ro
(I)
u.s. Patent
Jan. 17,2012
US 8,097,284 B2
Sheet 9 of9
- - - - - - - - -_........... ..............
100 .00%
90.00%
80.00%
II)
til
lIS
0::
.~
70.00%
60.00%
50.00%
> 4000%
~
:l
II)
30.00%
20.00%
10.00% .
0.00%
Larynx Cancer
Lung Cancer
Uterine Cancer
Types of Cancer
_ _. . ._.__._. _._._.~._ _J
Fig ure 9
US 8,097,284 B2
young Cuban woman. Ever since that event it has been in use
as an aggressive treatment for anti-tumor therapy.
Recently, blue scorpioll venom has been shown to have a
variety of health benefits including powerful anillgesic and
anti-inflammatory effects. In addition to Cilncer, blue scor
Priority is claimed to U,S, Provisional Patcnt Applicatjon
pion venom has been shown to have positive results with a
Ser. No. 60/987,756, filed on Nov, 13,2007, and titled "A nal
wide vilriety of immune-system related diseases including:
gesic, Antiinnammatory, Immunity Boosting, Antitumoral,
HIV; Alzheimer's Disease; Multiple Sclerosis; Muscular
and Cancer Preventing and Treating Methodology Using
Dystrophy; and Arthritis. During the last 15 years, over
Organic, Modified. and Magnetically Polarized Scorpion
Venom and Synthetics Thereof." This priority application is 10 6(),OOO peoplc outside the United States have taken blue scor
pion venom and witnessed great improvements in their lives.
incorporated by reference herein as though set forth herein in
Although blue scorpion venom has been used in the past to
full.
treat pain. inflammation. cancer, and other ailments the deliv
BACKGROUND OFTH E INVENTION
ery systems and scorpion venom solutions themselves have
15 been inconsistent. This made administration of an effective
This invention generally relates to analgesic and anti-tu
blue scorpion venom solutiondiflicult. Thus, there isa need in
mor solutions. Speeitieally, it pertains to a polarized dilute
the art for a blue scorpion venom solution that is stable, safe,
scorpion venom solution, a mcthod for making a polarized
effective. and consistent.
Moreover, blue scorpion venom, like many liquids, is most
dilute scorpion venom solution, and a method for administer
ing dilute scorpion venom solution. The polarized dilute scor 20 ellcctive when it is polarized.
pion venom solution relieves pain, improves immune-system
A polaril.ed Illiquid, as compared to non-polarized liquid, is
response, treats cancer, prevents cancer, improves quality of
absorbed far more rapidJy into the human body and is signifi
sleep, reduces inflammation, and minimizes negative biologi
cantly more bio-available on a cellular level, rcsulting in
cal response to chemotherapy and radiation treatment.
significantly improwd results. This has been tested in small
Around the world, research is being done on the potential 25 scale blind studies in which the cases did nOlknow whether or
effectiveness of scorpion venom as a cancer-fighting tool.
not they were receiving unpolarized liquid or polarized liq
Scientists have taken a synthetic version of venom of Leiurus
uid, In those cases where individuals aClually received polar
quillquesrriallls, also known as the Giant Yellow Israeli scor
ized/magnetized liquid, they reported signilicantly improved
pion. labeled it with radioactive iodine and found it to be an
results over those individuals who received non-polarized
effective delivery vehicle for targeted radiotherapy against 30 liquid. It is believed that the effects of the polarization process
stays crfectively within the liquid for three to four weeks
glioma. The synthetic venom binds to glioma cells and has an
unusual ability to pass through the blood-brain barrier that
before the liquid returns to a state similar to pre-polarization.
blocks most substances from reaching brain tissue from the
To pol arize scorpion venom, the venom is repeatedly exposed
bloodstream, The synthetic venom is used primarilly as a
to fixed magnetic fie:Jds aligns the magnetic poles of the
carrier to 'tmnspOl1 radioactive iodine to glioma cells, but 35 molecules within the scorpion venom liquid in such a way
there is data that suggests that it may also slow down the
that it forms a geometric consistency between the molecules
growth of tumor cells.
which influences the body's ability to recognize the liquid
Dr. M. A, A. Omran of Suez Canal University in Egypt
and open molecular gates for better absorption. This process
published the study "Cytotoxic and apoptotic effects of scor
preferably utilizes fixed magnets: however, electromagnets
pion uiurus ifuinqlleslrialus venom on 293T and C2C 12 40 may also be used. This process is an inlegral part of the
cubryotie cell lines" in the Journal of Venomous Animals
solution and method of the current invention and is explained
and Toxins including Tropical Diseases. Dr. Omran's study
in more detail below,
proves the venom from scorpions of the Buthidae family,
CUITenlly, scorpion venom solutions are not available in a
particularly Leiurus quinqueslriallls, produces apoptosis in
polarized liquid form . Thus, there is a need in the art for a
human cells. The most intriguing element of Dr. Omran's 45 polarized blue scorpion venom solution and a method for
slUdy was that it showed that scorpion venom produces both
making polarized blue scorpion venom solution.
apoptosis (cellular suicide) and necrosis (cellular death
As discussed above, blue' scorpion venom provides ben
through trauma), The key issue is concentration. At certain
efits to the human body lhrough apoptosis. Apoptosis is a
concentrations, scorpion venom resulted in apoptosis. In
biological mechanism through which cytotoxicity takes
other, larger concentrations. cytotoxicity shifted to necrosis. 50 place. Apoptosis diminishes unheallhy inflammatory
Like uiurus quillqILeslriallls, Rfwpalurus junceus (blue
response. improves efficacy of chemotherapy, supports
growth of healthy cellular tissue, and is essential to the body's
scorpion) belongs to the Buthidae family of scorpions. The
blue scorpion is indigenous to Eastern Cuba, Vcnezuela,
natural abili~y to destroy cancerous tumurs,
Haiti, and the Dominican Republic. Blue scorpion venom,
The process of apoptosis a major focus of research and the
has been used as a folk medicine in Easlern Cuba for genera- 55 development of new pharmaceutical drugs for the lreatment
tions. It was found that in a certain areas of Cuba when people
of: cancer; HIV; arlhritis; multiple Sclerosis; Alzheimer'S
Disease; a wide range of other auto-immune conditions; and
who had chronic conditions were stung by the blue scorpion,
their conditions surprisingly improved instead of gctting
supporting appropriate immune system response to organ
worse, In 1980, blue scorpion venom was researched in the
transplants.
Cuban province of Guantanamo, one of the areas where the 60
Because apoptosis is the primary mechanism hy which
blue scorpion is indigenous. Originally the chemicals ta.ken
blue scorpion venom relieves pain, improves immune-system
from the blue scorpion were used primarily to treat ailmcnts
response, treats cancer, prevents cancer, improves quality of
in animals. The effects upon animals were found to be
sleep, reduces inflammation, and minimiz.es negati ve biologi
extraordinary. Doctors then began to consider the positive
cal response to chemotherapy and radiation treatment. an
impact it could have upon the hcalth of humans, In the early 65 expanded understanding of apoptosis is required. The rol of
1990's. blue scorpion venom was tested on a human patient
cellular suicide in the formation of embryonic cells has been
and was found to shrink, and then eliminate, the lUmor of a
recognized [or a great deal of time, bUl what was not under
POLARIZED SCORPION VENOM SOLUTION
US 8,097,284 B2
to
J5
20
25
30
35
40
45
50
55
60
65
US 8,097,284 B2
her and
lery are
cry the
ncause
ding to
II DNA
ed p53.
.he p53
)(juced.
;lIs and
In ism if
cancer
Kadia
Ig: posi
'ivaI. or
vival of
IUlatiun
1 to the
)1' posi
~ukin-2
ytcs.
of oxi
lants or
~rapeu
,roperly
bind to
cell tu
nclude:
he TNF
;0 binds
ule that
. called
,ifferent
)ptosis.
I(inter
rs bind
~ mpho
rgcn.
,intrin
~ outer
d-2 on
~active
,wtein,
mern
~ cyto
'otense
~ ATP,
apop
Ile of a
.They
I each
:s and,
~. Thc
.p~nd
hlood
cstion
.chro
ixtl'in
or are
mains
!men
nits a
US 8,097,284 B2
10
15
20
25
)0
35
40
45
50
55
60
65
Mucous Mcml
Conditiun!Hd
study, all pan
healthy weigh
to any of the il
study and all \
was scientifie.
no toxic side e
Other featur
di lute blue SCI
will beeume n
following dcta
ings.
BRIEFI
FIG. 1 is an
the elTectivcnc
RG. 2 is an
the effectivene
reducer.
FIG. 3 is an
the effectivcne'
RG. 4 is an
the effectivene
ment in Ihe bo(
FIG. 5 isan i
the efficacy of
FIG. 6 isan i
the quality of I
scorpion venon
F1G.7isan i
the quality of
scorpion vcnon
FIG.8isani
the quality of I
scorpion vcnon
FIG. 9 isani
the survival mtl
that used blue,
In the 1'0110'
embodiment, n
ings that form a
illustration, as
may be practiCi
ments may be I
withoUl departi
In the follo\l
ments of the in~
in order to pn
as pects of one (
ever, one or IT
practiced withe
well-known Ill.
not 'been descril
aspects of cmb(
This inventic
venom solution
scorpion vcnon
izcd dilute blue
fe rred, the actil
Rhopa/urusjlllJ
extracted from
US 8,097,284 B2
9
Mucous Memhranes; Condition! Appearance of the Eyes ; and
Condition!Health of Internal Organs. Over the course of this
study, all participants rem<lined healthy. They maintained
he<llthy weight and levels of activity. No hurm was indic<lted
to any or the internal organs of those who participated in the
study and all were in healthy working order. In summary, it
was scientifically determined that blue scorpion venom h<l5
no tQxic side effects.
Other features and advantages are inherent in the polarized
di'lute blue scorpion venom solution claimed and disclosed
will become apparent to those skilled in the art from the
following detailed description and its accompanying draw
ings.
10
US 8,097,284 B2
11
12
scorpions in each cage: preferably a roach for every two
animals, or an adult cricket for every animal.
Venom extraction is preferably performed every month.
The scorpions should be milked for their venom on a monthly
basis , preferably, by highly trained stafF. The venom is
extracted by a mild electro-shock placed briefly on the tail of
the scorpion which encourages the scorpion to release its
venom. This shock causes no physical damage to the scor
pion, nor does it shorten the lifc span or the scorpion. The
10 venom is then collecte<l into a small cup and placed in refrig
erated storage to maintain the quality of the venom. Food is
given a week after venom extraction in order to allow lime for
the animals to recover from any stress associated with the
venom extraction. If they are fed before the extraction, the
15 quantity of venom produced can be affected.
Storage and transportation of the venom. Once extracted,
the venom is preferably kept in a locked refrigeration unit.
Preferably, the venom is regularly transported from the biot
erium to a production facility. If the production facility is in
20 the United States it should be an FDA licensed. production
facility. When transported, the venom is preferably main
tained in a temperature controlled. double-sealed container
for added safety and to maintain venom quality.
Production of the dilute scorpion venom solution.
25
As noted above, the first stage of production of the dilute
scorpion venom solution of the present invention is extrac
tion. Individual "crops" of scorpions are extracted every 30
duys. These crops are kept separatcd [rom one another, but are
given the same diet. Thisconsistency in diet, timing of extrac
.10 tion, and population control is intended to support consis
tency of concentration of venom per each extraction.
Preferably, a one hundred milliliters (100 ml) glass con
tainer. The container can be empty, as preferred, or fi !Jed with
of medical disti lied water, which is uscd for extraction. Using
35 elcl:trical stimulation of each scorpion's tail, drops of scor
pion venom will he captured in this 100 ml glass container.
Into each 100 ml container, approximately two hundred (200)
drops of venom arc extracted with an average of 2.SS drops
from each scorpion.
40
llhe second step is transportation. Once extraction is com
pleted, the container is sealed and placed into a refrigerated
environment. The container should be kept in that refrigerated
I!nvironment for thirty minutes until the venom reaches a
maximum of twelve degrees centigrade (12 C (S2 F)). At that
4S time, the container should he packed into a refrigerated com
partment which keeps an even temperaturc range between 12
and 14 C (S2-S~ F) for 4!l hours. These times and tempera
tures an.: prl!fem:d, hut a wide variety of times and tempera
tures are acceptable without deviating from the scope of the
50 invention.
The third step is receiving. The manufacturing (preferably
pharmaceutical) laboratory receives the concentrated venom
solution. This concentrate should be hroughtto the laboratory
facility. This concentrate should he received in individual
55 containers ranging in size from 100 ml to SOO ml.
The fourth step is initial storage. The laboratory mllst
immediately refrigerate the concentratc. As noted ahove, the
concentrate is preferahly received by the laboratory in a
refrigerated container. Concelllrate is prefera'h ~y refrigerated
60 and maintained ata range between 12 to 14 C (52 F-58 F). The
concentrate degrades at an accelerated rate when exposed to
bright light; as such, this refrigerated storage environment
should hI! protected from light and without internal illumina
tion.
65
The fifth step is filtration. Scorpion venom is a complex
mixture of salts, small molecules, peptides, and other pro
tei ns. The laboratory should filter the venom usi ng glass nher
memhra!
pcs. Tili
venom. '
filtered i
The sl
venom i.
water to
withina:
is transfe
Contaillel
Detcrn
scorpion
0.99lJ7
rr
solution)
Concclltr
stages of,
prepared
The til
shipped i
The vc
suspcndcl
consisten
is prcfcral
than 10 Ill:
tainers. D
should he
The fin"
bulk prodl
individual
tight seals.
from degru
containers
uct. The pr
sure to air
potency of
the prodUl:t
be extende
removal frl
ever, if bOil
ment (lowe]
production
periodofpr
ized boltlin
chilled disti
ated envinll
Once the
produci are
maintained.
C (S2 F and
The dilut
bacterial COl
tration. Stan
preferably u
a customer l
Standard]
determining
tatively eval
dures, know!
rejected ifha
more than 5'
naturally fOL
conccntratio ]
concentratiOi
venom.
Polarizatil
ahly, the dilul
polarizing bl
US 8,097,284 B2
14
13
ITIclllbran..: filler that is prefcrably 0.80 !-un. 25 mlTl. I pkl50
pcs. This ensures the sterilization and puritlcation of the
venom. The venom from a crop of scorpions is extracted and
filtcred into a single. stelilized glass container.
The sixth step is bulk manufacturing. After filtration. the
v(;nom is comhined with chilkd, medical-quality distilled
water to achieve a specillcally maintained concentration
within a sterilized environment. A bulk version of the product
is transferred into a seakd , sterili/.ed huJk containcr and the
container then transferred into to a refrigerated environment.
Determining the concentration . Typically, the dilute hlHe
scorpion venom solution contains 0.OOD3 ml of venom per
D.9997 ml of distilled water (totaling I ml of prepared dilute
solution) for treatment of third and fourth stages of cancer.
Concentration for treatment of baseline, first , nnd second
stages of cnncer is preferably 0.00025 ml of venom in I ml of
prepared dilute solution.
The final bul'k dilute solution is preferably stored and
shipped in a dark and refrigerated environment.
The venom has tendency to separate from water when
suspended in water foran extended period of time. To achieve
consistent concentration of venom, the scaled hulk container
is preferably agitated in a hack and forth manner for no kss
than :>0 minutes hefore being transferred into individual con
tainers. During the packnging process the bulk container
should he continuously agitated through stirring.
The linal step of the process is packaging and hottling. The
bulk product is transferred in a sterilized environment into
individual one liter hottles, which should include labels. air
tight seals, and opaque containers, which protect the product
from degradation due to inappropriate exposure to light. The
containers are pre-sterilized before being filled with the prod
uct. The process of packaging is time sensitive. Undo expo
sllre to air and cxcessiv(: temperatures will undermine the
potency of the venom. As such, time is a scnsitive issue with
the product. Exposed to room temperature, the process cannot
be extended past a few (approximately four) hours from
removal from refrigcration to completion of bottling. How
ever. if bottling is done in a highly air conditioned environ
ment (lower than 15 Cor 58 F) or if the distilled water used in
production is chilled (through prior refrigeration) then the
period of production from removal from refrigeration to final
ized holtling c;an be extended. Eight (8) hours for highly
chilled distilled water; twelve (12) hours for highly refriger
ated environment.
Once the bottling procedure is complete. bottles of final
product are to be storcd in a dark, refrigerated environment
maintained. as preferred, at a temperature hetween 12 and 14
C (52 F and 58 F) where they will wait until final shipping.
The dilute blue scorpion venom is preferably tested for
bacterial contaminants. chemical contaminants, and concen
tration. Standard microbial and mass spectrometry tests are
preferably used . If possihle. no product should be shipped to
a customer until the batch has undergone testing for purity.
Standard testing procedures. such as Lowry's method for
determining protein concentration should be used to quanti
tatively evaluate the dilute solution. Other types of proce
dures, known in the art , may also be used. Batches should be
rejected if hactcrial or chemical contaminants arc found, or if
more than 5% of the bottles test for levels of any chemical
naturally found within the venom, but at a higher or lower
concentration in excess of 10% deviation from the standard
concentration per standardized mass spectrometry of the
venom.
Polarization of the dilute scorpion venom solution. Prefer
ably. the dilute solution is polarized. The prefen-ed process for
polarizing blue scorpion venom is the Mikaelian Polarized
10
15
20
25
30
35
40
45
50
55
60
65
US 8,097,284 B2
15
16
10
t5
20
25
30
35
40
45
50
55
60
65
compress(
separation
process.
The thi l
and recep t
sandwich
the hose i~
end of all(
tainer. Th l
pump. Th(
any pump i
The fou
distilled '"
venom or
mixture of
pump is tu
the contain
then back
gallons pe l
length and
polarized.
process 01'1
shorter the
Intense I
of Mikaelii
Resistance
magnets at
utilize mag
cess utilize
tion. Liquil
(IMR) fie ll
strongly af
ecules and 1
ecules in a
Polariz.al
The realig l
Intense Ma:
uti Iization I
lular level. I
distinctive
The polariz
liquid to be
the positiVt
thoroughly
cer ce.11 mel
tion of seor
cient triggel
within cane
inhibiting t
Addition.
blue scorpi
Several SI
venom in tre
discussed al
eight thous~
study, 8,30 ~
were given I
studied wit~
being theml
and utel1lS ~
study.
The resea
history of e.
patient thrOi
was evaluat(
US 8,097,284 B2
17
compresscd to a preferred distance no less than 3 mm in
separation. compressing the plastic transparent hose in the
process.
The third step of the process is connection of hose, pump.
and receptacle. One end of the hose affixed to the magnetic
sandwich is connected to an electric pump. The other end of
the hose is deposited in a container. From that container the
end of another hose of equal diameter is placed in the con
tainer. The opposite of this hose is affixed to the electric
pump. The pump is preferahly an electric pump, hut may he
any pumping or actuating device that circulates the fluid.
The fourth step is recirculation. The container is filled with
distilled water or a mixture of distilled water and scorpion
venom or a mixture of distilled water and nutrients or a
mixture of distilled water, nutrients. and scorpion venom. The
pump is turned on and the liquid is made to recirculate from
the container. through the magnetic sandwich to the pump and
then hack to the container at a rate of approximately 190
gallons per hour. This process of recirculation is repeated at
length and will vary based upon the amount of liquid heing
polarized. The greater the amount of liquid; the longer the
process of polarilation is. The lesser the amount of liquid; the
shorter the process of polarization is.
Intense Magnetic Resistance (IMR). The unique clement
of Mikaelian Polarized Liquid is creation of Intense Magnetic
Resistance (IMR) by utilizing similar poleeVcharged sides of
magnets at very close distances. Other forms of polarization
utilize magnetic attraction. while Mikaelian Polarization Pro
cess utilizes magnetic repulsion as a mechanism for polariza
tion. Liquids tlowing through Intense Magnetic Resistance
(IMR) fields are suhject to molecular polarization which
strongly affects the geometric relationships between mol
ecules and the electromagnetic fields surrounding those mol
ecules in a way which is commercially significant.
Polarization enhances utilization of water and nutrients.
The realignment of magnetic poles of molecules using
Intense Magnetic Resistance (lMR) enhances ahsorption and
utilization of water, nutrients, and scorpion venom on a cel
lular level. In pm1icular, the cell membranes of cancer have a
distinctive and excessive negative electromagnetic charge.
The polarization of liquid allows for the molecules within the
liquid to be uti~ized with extreme efficiency by cancercells, as
the positive electromagnetic poles of these molecules are
thoroughly attracted to the excessive negative charge of can
cer cell membranes. Specific to this application, the utiliza
tion of scorpion venom molecules leads to a rapid and effi
cient triggering of apoptosis (programmed cellular suicide)
within cancer cells; thereby accelerating their death and
inhihiting the growth of cancerous tumors.
Additional information on the cancer fighting ability of
blue scorpion venom.
Several studies have shown the efticacy of blue scorpion
venom in treating and fighting cancer. One of these studies, as
discussed ahove, was a third stage clinical trial involving
eight thousand three hundred and two (8.302) patients. In this
study, 8,302 patients of a variety of different stages of cancer
were given blue scorpion venom . A variety of cancers were
studied with breast. brain, lung, prostate, and colon cancers
being the most common studied. Cancers of the larynx, lung,
and uterus showed the greatest benefit over the course of the
study.
The researches of the trial used summaries of the clinical
history of each patient issued by the doctor who tracks the
patient through different medical institutions. Each patient
was evaluated monthly. During the evaluation , doctors spoke
18
-US 8,097,284 B2
19
20
10
15
20
25
30
35
40
45
50
55
60
65
andimpi
scorpiOlJ
in health
Multi.
correlati.
siveord
playing~
is conclL
prolifera:
responsi1
Impon
and inhit
with heal
trials disc
inflamm.:
health w
reversed
have by
MoreoveJ
exposed I
Bluesc
but does.
reasons. =
viable nUl
out nutrit:
division.
proteins.
venom pi
therebyce
cer cell P'
scorpion"
nels on C3I
healthy ce
in blue Be
potassium
rapidabsc
Blue sc.
firms that
variety of
lung; boo.
Blue g.
Research
venom fre
improved
remission
have used
rienced th
dependent
vitalorgar
Iifestyled
Some in
blue scorp:
responseu
appetite, f
improvedt
immune-s)
Admini!
venom is I
also have I
different f(
istration. A
ensure the
Nasal adn
patients wi
tems. This
extremepa
the respirat
US 8,097,284 B2
21
and improved motor skills. These responses indicate that blue
scorpion venom somehow interacts with the nervous system
in healthy. regulatory way.
Multiple research beginning in the 1950's have shown a
correlation between extreme nervous system activity (exces
sive or deficient) and aggressive tumor cell proliferation. By
playing a positive regulatory role with the nervous system. it
is concluded that blue scorpion venom inhibits cancer cell
proliferation through the support of healthy neurological
responsiveness.
Importantly. blue scorpion venom produces cytotoxicity
and inhibits cell functionality only with cancer cells and not
with healthy normal cells. In the eight-year third stage clinical
trials discussed above, patients consistently experienced anti
inflammatory responses. diminished pain, and improved
health while cancerous tumors expressed diminished or
reversed cell proliferation. The results of the clinical trials
have by independently confirmed by additional research.
Moreover, in vitro experiments also confirm that cancer cells
exposed to blue scorpion venom experience cytotoxicity.
Blue scorpion venom produces cytotoxicity in cancer cells,
but does not produce cytotoxicity with healthy cells for two
reasons. First, cancer cells identify proteins in venom as
viable nutrient. Cancer cells are known to aggressively seek
out nutrients in their environment to support rapid cellular
division. Blue scorpion venom is extremely rich in a variety of
proteins. Cancer cells may misidentify and ingest these
venom proteins far more aggressively than healthy cells.
thereby creating a much higher absorption rate. Second. can
cer cell potassium channels provide greater access to blue
scorpion venom absorption. The structure of potassium chan
nels on cancer cells are often distinct from those of found on
healthy cells. The unique electrostatic charge of the proteins
in blue scorpion venom may be particularly drawn to the
potassium channels of cancer cells resulting in much more
rapid absorption.
Blue scorpion venom as a cancer treatment. Research con
firms that blue scorpion venom is effective in treating a wide
variety of cancers including cancers of the: prostate; colon;
lung; brain; digestive tract; breast; and cervix.
Blue scorpion venom and common health benefits.
Research shows that patients administered blue scorpion
venom frequently experience the following health benefits:
improved quality of life; increased survival rate; and tumor
remission lasting five or more years. 89.5% of patients who
have used blue scorpion venom in their treatment have expe
rienced these benefits. As stated above, these benefits are
dependent upon stage of cancer, genetic issues. condition of
vital organs, continued exposure to environmental toxicity.
lifestyle choices of the patient. and other factors.
Some initial changes in the quality oflife of a patient using
blue scorpion venom include: minimized negative biological
response to chemotherapy and radiation treatment; increased
appetite, as well as a mid-term increase in body mass;
improved quality of sleep; pain relief; and improved patient
immune-system response.
Administration of blue scorpion venom. Blue scorpion
venom is primarily administered orally. Some patients may
also have blue scorpion venom administered via additional
different formats. Oral is the most common form of admin
istration. A patient may be given certain dietary restrictions to
ensure the greatest effectiveness of blue scorpion venom.
Nasal administration, through a nasal spray, is best for
patients with cancers related to the nervous and skeletal sys
tems. This administration also works well for patients in
extreme pain. For patients with cancers specifically related to
the respiratory system. an aerosol administration of blue scor
22
herein in full.
US 8,097,284 B2
24
23
Rajendra, W., Arunmozhiarasi, A., Jeyaseelan, K. Toxins in
anti-nociception and anti-inflammation. Toxicon; 2004 44
J,ppl-17.
Xiong, Y. M., Lan, Z. D., Wang, M., Liu, B., Liu, X. Q.
Molecular characterization ofa new insect neurotoxin with
an analgesic effect on mice from the scorpion Buthus mar
tensi Karsch. Toxicon 1999; 37 8, pp. 1165-1180.
In summary, the present invention is a polarized dilute
scorpion venom solution, a method for making a polarized
dilute scorpion venom solution, and a method for administer
ing dilute scorpion venom solution. The polarized dilute scor
pion venom solution relieves pain, improves immune-system
response, treats cancer, prevents cancer, improves quality of
sleep, reduces inflammation, and minimizes negative biologi
cal response to chemotherapy and radiation treatment.
The foregoing description of the preferred embodiment of
the invention has been presented for the purposes of illustra
tion and description. While mUltiple embodiments are dis
closed, still other embodiments of the present invention will
become apparent to those skilled in the art from the above
detailed description, which shows and describes illustrative
embodiments of the invention. As will be realized, the inven
tion is capable ofmodifications in various obvious aspects, all
without departing from the spirit and scope of the present
invention. Accordingly, the detailed description is to be
regarded as illustrative in nature and not restrictive. Also,
although not explicitly recited, one or more embodiments of
the invention may be practiced in combination or conjunction
with one another. Furthermore, the reference or non-refer
10
15
20
25
* * *
* *